Understand the source comparison
Comparing Peptide Mechanisms — What the Research Shows vs Marketing Claims
BPC-157 VEGF/FGF-2 upregulation; FAK-paxillin pathway activation 30–50% faster callus formation; improved bone mineral density; enhanced angiogenesis 10 g/kg to 10 mg/kg (animal); human data absent Often marketed as 'heals everything'. Actual evidence confine
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF/FGF-2 upregulation; FAK-paxillin pathway activation
- 30–50% faster callus formation; improved bone mineral density; enhanced angiogenesis
- 10 μg/kg to 10 mg/kg (animal); human data absent
- Often marketed as 'heals everything'. Actual evidence confined to GI, tendon, and bone in animal models
- Moderate (multiple animal studies, no human RCTs)
- TB-500
- Actin regulation; anti-inflammatory cytokine modulation
- Reduced fibrosis in healing tissue; improved cellular migration; faster soft tissue integration
- 2–10mg, 2–3× weekly (animal protocols)
- Marketed as 'muscle builder'. Primary evidence is tissue repair, not hypertrophy
- Moderate (cardiac and tendon repair data stronger than bone-specific)
- GHK-Cu
- Copper delivery for lysyl oxidase; collagen crosslinking enhancement
- 2× increase in alkaline phosphatase activity; improved collagen maturation; enhanced osteoblast differentiation
- 1–3mg per dose
- Confused with general 'copper supplements'. Chelated form required for bioavailability
- Low-Moderate (strong in vitro data, limited in vivo bone-specific studies)